Table 2.
Relationship between nuclear ADA3 and nuclear c-MYC co-expression groups and clinico-pathological parameters within the whole unselected invasive breast cancer series (n = 588 cases)
| Parameters | ADA3 Nuclear c-MYC Nuclear expression phenotypes | ||||||
|---|---|---|---|---|---|---|---|
| ADA3low c-MYClow
N (%) |
ADA3high c-MYClow
N (%) |
ADA3low c-MYChigh
N (%) |
ADA3high c-MYChigh
N (%) |
X 2 | P | ||
| Patient age | ≤50 | 66 (31.7) | 24 (11.5) | 65 (31.1) | 53 (25.5) | 1.862 | 0.602 |
| >50 | 106 (28.0) | 45 (11.9) | 113 (29.8) | 115 (30.3) | |||
| Menopausal Status | Pre | 66 (30.4) | 25 (11.5) | 68 (31.3) | 58 (26.7) | 0.907 | 0.871 |
| Post | 106 (28.6) | 44 (11.9) | 110 (29.7) | 110 (29.7) | |||
| Tumor size | ≤2 cm | 96 (28.0) | 14 (12.0) | 99 (28.9) | 107 (31.2) | 2.765 | 0.429 |
| >2 cm | 76 (31.4) | 28 (11.6) | 77 (31.8) | 61 (25.2) | |||
| Tumor grade | 1 | 20 (23.5) | 14 (16.6) | 17 (20.0) | 34 (40.0) | 32.961 | <0.001 |
| 2 | 47 (25.3) | 18 (9.7) | 48 (25.8) | 73 (39.2) | |||
| 3 | 105 (33.3) | 37 (11.7) | 112 (35.4) | 62 (19.6) | |||
| Tubules | 1 | 5 (22.7) | 7 (31.8) | 5 (22.7) | 5 (22.7) | 13.345 | 0.037 |
| 2 | 47 (25.1) | 21 (11.2) | 59 (31.6) | 60 (32.1) | |||
| 3 | 116 (32.7) | 35 (9.9) | 107 (30.1) | 97 (27.3) | |||
| Pleomorphism | 1 | 1 (14.3) | 1 (14.3) | 3 (42.9) | 2 (28.6) | 29.138 | <0.001 |
| 2 | 57 (26.0) | 31 (14.2) | 46 (21.0) | 85 (38.8) | |||
| 3 | 110 (32.6) | 31 (9.2) | 122 (36.2) | 74 (22.0) | |||
| Mitosis | 1 | 43 (24.6) | 23 (13.1) | 40 (22.9) | 69 (39.4) | 23.706 | 0.001 |
| 2 | 30 (29.1) | 9 (8.7) | 30 (29.1) | 34 (33.0) | |||
| 3 | 95 (33.2) | 31 (10.8) | 101 (35.3) | 59 (20.6) | |||
| Axillary nodal stage | 1 | 93 (28.5) | 42 (12.9) | 90 (27.6) | 101 (31.0) | 6.617 | 0.353 |
| 2 | 57 (28.2) | 23 (11.4) | 68 (33.7) | 54 (26.7) | |||
| 3 | 22 (37.3) | 4 (6.8) | 20 (33.9) | 13 (22.0) | |||
| NPI | Good | 30 (19.2) | 21 (13.5) | 39 (4) | 66 (25.0) | 33.968 | <0.001 |
| Moderate | 103 (33.0) | 40 (12.8) | 88 (8.8) | 81 (28.2) | |||
| Poor | 39 (33.1) | 8 (6.8) | 50 (36) | 21 (17.8) | |||
| Lymphovascular Invasion | Negative | 106 (28.0) | 52 (13.8) | 103 (27.2) | 117 (31.0) | 10.624 | 0.014 |
| Positive | 64 (31.4) | 16 (7.8) | 75 (36.8) | 49 (24.0) | |||
| Tumor type | Invasive Ductal/NST | 123 (34.6) | 39 (11.0) | 120 (33.7) | 74 (20.8) | 61.858 | <0.001 |
| Invasive Lobular | 13 (22.4) | 8 (13.8) | 4 (6.9) | 33 (56.9) | |||
| Medullary-like | 2 (11.1) | 3 (16.7) | 9 (50.0) | 4 (22.2) | |||
| Excellent Prognostic Special types* | 5 (25.0) | 6 (30.0) | 5 (25.0) | 4 (20.0) | |||
| Tubular Mixed | 20 (20.6) | 11 (11.3) | 28 (28.9) | 38 (39.2) | |||
| Mixed NST & Lobular | 4 (19.0) | 2 (9.5) | 6 (28.6) | 9 (42.9) | |||
| Mixed NST &other special types | 2 (25.0) | 0 | 3 (37.5) | 3 (37.5) | |||
N = number of cases. c. = cytoplasmic, n. = nuclear expression. NST = No Special Type. NPI = Nottingham Prognostic Index
Analysis of all patient specimens from the unselected invasive breast cancer cohort demonstrates a significant correlation between nuclear ADA3 and c-MYC levels in the areas of tumor grade, pleomorphism, tubule formation, mitotic scores, NPI, and tumor type across the four groups
The bold font indicate that the clinical correlation is statistically significant < 0.05